We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$45.1M
1-Year Est. Return
74.25%
This Fund
S&P 500
This Quarter
Est. Return
-5.44%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.92B
AUM Growth
-$82.3M
(-4.1%)
Cap. Flow
-$215M
Cap. Flow
% of AUM
-11.22%
Top 10 Holdings %
Top 10 Hldgs %
52.67%
Holding
387
New
94
Increased
95
Reduced
80
Closed
99
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$12.5M |
| 2 |
Abbott
ABT
|
+$10.5M |
| 3 |
Outlook Therapeutics
OTLK
|
+$7.71M |
| 4 |
BPTH
Bio-Path Holdings Inc
BPTH
|
+$7.56M |
| 5 |
SHPG
Shire pic
SHPG
|
+$5.34M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$22.6M |
| 2 |
Biogen
BIIB
|
+$7.14M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$3.88M |
| 4 |
Neurocrine Biosciences
NBIX
|
+$3.22M |
| 5 |
ESRX
Express Scripts Holding Company
ESRX
|
+$2.84M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 12.85% |
| 2 | Industrials | 0.12% |
| 3 | Consumer Staples | 0.07% |
| 4 | Consumer Discretionary | 0.06% |
| 5 | Technology | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DRRX
76
DELISTED
DURECT Corp
DRRX
| $3.1M | 0.16% |
+254,028
| New | +$3.26M |
|
|
ACHN
77
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
| $2.98M | 0.16% |
3,827
+1,529
| +67% | +$13.1K |
|
78
Iovance Biotherapeutics
IOVA
$2.09B
| $2.98M | 0.16% |
367,242
-45,004
| -11% | -$283K |
|
79
Precigen
PGEN
$1.98B
| $2.96M | 0.15% |
121,442
+8,528
| +8% | +$242K |
|
|
ALPN
80
DELISTED
Alpine Immune Sciences Inc
ALPN
| $2.95M | 0.15% |
160,373
-5,142
| -3% | -$91.3K |
|
81
Illumina
ILMN
$29.6B
| $2.81M | 0.15% |
+20,560
| New | +$2.92M |
|
|
VXZ
82
DELISTED
iPath S&P 500 VIX Mid-Term Futures ETN due 1/30/2019
VXZ
| $2.81M | 0.15% |
65,000
-10,000
| -13% | -$440K |
|
|
FOCL
83
EDAP TMS S.A.
FOCL
$231M
| $2.8M | 0.15% |
+847,225
| New | +$2.93M |
|
|
84
PUT
Precigen
PGEN
$1.98B
| $2.8M | 0.15% |
1,146
+123
| +12% | +$3.49K |
|
|
ITCI
85
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $2.79M | 0.15% |
71,943
-6,057
| -8% | -$218K |
|
|
PVLA
86
Palvella Therapeutics
PVLA
$2.09B
| $2.6M | 0.14% |
20,200
+18,012
| +823% | +$2.76M |
|
|
SGMO
87
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $2.55M | 0.13% |
4,400
+1,395
| +46% | +$8.89K |
|
|
CEMP
88
CALL
DELISTED
Cempra, Inc.
CEMP
| $2.54M | 0.13% |
1,537
+493
| +47% | +$8.7K |
|
89
PUT
Opko Health
OPK
$1.17B
| $2.47M | 0.13% |
2,645
+1,550
| +142% | +$15.7K |
|
|
OPGN
90
DELISTED
OpGen, Inc
OPGN
| $2.47M | 0.13% |
+16
| New | +$2.2M |
|
|
ADVM
91
DELISTED
Adverum Biotechnologies
ADVM
| $2.46M | 0.13% |
77,993
+23,930
| +44% | +$1.08M |
|
|
SIOX
92
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $2.44M | 0.13% |
23,750
+19,495
| +458% | +$1.95M |
|
93
VistaGen Therapeutics
VTGN
$9.85M
| $2.43M | 0.13% |
+20,777
| New | +$2.38M |
|
|
94
Biogen
BIIB
$31.6B
| $2.42M | 0.13% |
10,000
-27,077
| -73% | -$7.14M |
|
|
95
PUT
Biogen
BIIB
$31.6B
| $2.42M | 0.13% |
100
-952
| -90% | -$251K |
|
|
LJPC
96
CALL
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $2.33M | 0.12% |
+1,458
| New | +$26.2K |
|
|
ZGNX
97
DELISTED
Zogenix, Inc.
ZGNX
| $2.33M | 0.12% |
289,200
+34,776
| +14% | +$339K |
|
98
PUT
Ionis Pharmaceuticals
IONS
$8.93B
| $2.29M | 0.12% |
984
+798
| +429% | +$25.7K |
|
|
IRD
99
Opus Genetics
IRD
$286M
| $2.28M | 0.12% |
18,898
-8,628
| -31% | -$1.21M |
|
100
PUT
Vertex Pharmaceuticals
VRTX
$125B
| $2.24M | 0.12% |
260
+227
| +688% | +$19.6K |
|
Similar funds
CG
OC
ICCON
PCM
CAS
CM
MCMC
CTC
Sabby Management's Q2 2016 Portfolio in Review
As of Q2 2016, Sabby Management held 387 positions worth $1.92B, down 4.1% from $2B the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Sabby Management withdrew a net $215M in Q2 2016, closing 99 positions and reducing 80 holdings. Its most notable exit was State Street SPDR S&P 500 ETF Trust, an estimated $22.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 12% a quarter earlier, followed by Industrials and Consumer Staples.
Against the trend, Sabby Management opened a new position in Abbott worth $10.4M.
- Sabby Management's largest Q2 2016 buy was Abbott: 264,700 shares worth $10.4M.
- Sabby Management added most to Regeneron Pharmaceuticals in Q2 2016, an estimated $12.5M increase.
- Sabby Management's biggest Q2 2016 reduction was Biogen, cutting an estimated $7.14M.
- Sabby Management fully exited State Street SPDR S&P 500 ETF Trust in Q2 2016, selling an estimated $22.6M.
- Sabby Management's ten largest holdings make up 53% of its $1.92B portfolio in Q2 2016.
- Sabby Management opened 94 new positions and closed 99 in Q2 2016.
- Sabby Management's portfolio value fell 4.1% quarter-over-quarter to $1.92B.
Based on Sabby Management's 13F filing for Q2 2016, filed 15 Aug 2016.